Literature DB >> 19078450

Should a war criminal be rewarded with eponymous distinction?: the double life of hans reiter (1881-1969).

D J Wallace1, M Weisman.   

Abstract

The combination of arthritis, urethritis, conjunctivitis, often associated with a psoriasiform rash has been termed Reiter's syndrome, particularly if the patient is HLA-B27 positive. In this report, the history of "Reiter's syndrome" is investigated by reviewing descriptions of the syndrome and the life and times of Hans Reiter from source materials and recent publications that shed new light on medicine and clinical research in the Nazi regime. The description of the syndrome clearly antedates Reiter's work by several hundred years. Numerous other investigators accurately described a reactive cutaneo-arthropathy before Reiter. Hans Reiter gave his imprimatur to some of the most horrific experiments conducted on concentration camp internees during World War II. We conclude that Reiter does not deserve eponymous distinction. The disorder should be renamed "reactive cutaneo-arthropathy," or a "reactive arthritis" syndrome.

Entities:  

Year:  2000        PMID: 19078450

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  4 in total

Review 1.  HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.

Authors:  Inés Colmegna; Raquel Cuchacovich; Luis R Espinoza
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  [Reiter disease or reactive arthritis?].

Authors:  S Eppinger; J Schmitt; M Meurer
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

3.  Nazi Medicine-Part 2: The Downfall of a Profession and Pernkopf's Anatomy Atlas.

Authors:  Erdem Bagatur
Journal:  Clin Orthop Relat Res       Date:  2018-11       Impact factor: 4.176

4.  [History of reactive arthritis. Historical milestones and future].

Authors:  H Zeidler
Journal:  Z Rheumatol       Date:  2022-08-25       Impact factor: 1.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.